Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY25 results Revenue from operations at Rs 2,002 crore, up 20.4% YoY and 10.3% QoQ. EBITDA margins at 20.8% with EBITDA up 26.1% YoY and 15.8% QoQ. PAT at 202 crore, up 38.2% YoY with PAT margins at 10.1%. Domestic business sales at 933 crore, up 15.4% YoY. International business sales at 1,069 crore, up 25.0% YoY. Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said: “Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business. Our recent inorganic additions – Sanofi partnership in India and Mantra acquisition in Canada – are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies, while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains.” Result PDF